Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.

Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ.

J Pharmacol Exp Ther. 2011 Mar;336(3):767-78. doi: 10.1124/jpet.110.172866. Epub 2010 Nov 30.

3.

Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys.

Do Carmo GP, Polt R, Bilsky EJ, Rice KC, Negus SS.

J Pharmacol Exp Ther. 2008 Sep;326(3):939-48. doi: 10.1124/jpet.108.138180. Epub 2008 May 29.

5.

Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.

Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M.

Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10.

PMID:
16530171
6.
7.

Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.

Wang YJ, Tao YM, Li FY, Wang YH, Xu XJ, Chen J, Cao YL, Chi ZQ, Neumeyer JL, Zhang A, Liu JG.

J Pharmacol Exp Ther. 2009 Apr;329(1):306-13. doi: 10.1124/jpet.108.142802. Epub 2009 Jan 9.

8.

Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice.

Matsumoto K, Narita M, Muramatsu N, Nakayama T, Misawa K, Kitajima M, Tashima K, Devi LA, Suzuki T, Takayama H, Horie S.

J Pharmacol Exp Ther. 2014 Mar;348(3):383-92. doi: 10.1124/jpet.113.208108. Epub 2013 Dec 17.

9.

MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.

Matsumoto K, Takayama H, Narita M, Nakamura A, Suzuki M, Suzuki T, Murayama T, Wongseripipatana S, Misawa K, Kitajima M, Tashima K, Horie S.

Neuropharmacology. 2008 Aug;55(2):154-65. doi: 10.1016/j.neuropharm.2008.05.003. Epub 2008 May 9.

PMID:
18550129
10.

Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.

Healy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD Jr, Coop A, Matsumoto RR.

ACS Chem Neurosci. 2013 Sep 18;4(9):1256-66. doi: 10.1021/cn4000428. Epub 2013 Jun 11.

11.

[Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.

Riba P, Ben Y, Nguyen TM, Furst S, Schiller PW, Lee NM.

Curr Med Chem. 2002 Jan;9(1):31-9.

PMID:
11860345
12.

Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.

Vanderah TW, Bernstein RN, Yamamura HI, Hruby VJ, Porreca F.

J Pharmacol Exp Ther. 1996 Jul;278(1):212-9.

PMID:
8764354
13.

Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.

Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K.

Neuropsychopharmacology. 2004 Sep;29(9):1656-63.

14.
15.

LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.

Tao YM, Li QL, Zhang CF, Xu XJ, Chen J, Ju YW, Chi ZQ, Long YQ, Liu JG.

Eur J Pharmacol. 2008 Apr 28;584(2-3):306-11. doi: 10.1016/j.ejphar.2008.02.028. Epub 2008 Feb 19.

PMID:
18353307
16.

Antinociceptive profile of biphalin, a dimeric enkephalin analog.

Horan PJ, Mattia A, Bilsky EJ, Weber S, Davis TP, Yamamura HI, Malatynska E, Appleyard SM, Slaninova J, Misicka A, et al.

J Pharmacol Exp Ther. 1993 Jun;265(3):1446-54.

PMID:
8389867
17.

Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.

Horan PJ, Wild KD, Kazmierski WM, Ferguson R, Hruby VJ, Weber SJ, Davis TP, Fang L, Knapp RJ, Yamamura HI, et al.

Eur J Pharmacol. 1993 Mar 16;233(1):53-62.

PMID:
8386089
18.

Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].

Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ.

J Med Chem. 2004 Mar 11;47(6):1400-12. Erratum in: J Med Chem. 2004 May 6;47(10):2716.

PMID:
14998329
19.

Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities.

Hu M, Giulianotti MA, McLaughlin JP, Shao J, Debevec G, Maida LE, Geer P, Cazares M, Misler J, Li L, Dooley C, Ganno ML, Eans SO, Mizrachi E, Santos RG, Yongye AB, Houghten RA, Yu Y.

Eur J Med Chem. 2015 Mar 6;92:270-81. doi: 10.1016/j.ejmech.2014.12.049. Epub 2014 Dec 29.

PMID:
25559207
20.

Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.

Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM.

J Pharmacol Exp Ther. 2005 Nov;315(2):821-7. Epub 2005 Aug 2.

Supplemental Content

Support Center